Amphista Therapeutics
PrivateLast Round
Series B
Extension
Dec 13, 2022
Total Funding Raised
$60.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Amphista Therapeutics is a biotechnology company that develops next-generation targeted protein degradation therapeutics for the treatment of cancer and other severe diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amphista Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Amphista Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 13, 2022 | ||||
| Series B | Mar 17, 2021 | ||||
| Series A | Apr 7, 2020 | ||||
| Seed | Dec 20, 2017 |
Key People
Founding team and executive leadership
Amphista Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B |
| BioMotiv | Series B, Series A |
| Forbion | Series B |
| Advent Life Sciences | Series B, Seed, Series B Extension, Series A |
| European Investment Fund | Seed, Series A |
| Gilde Healthcare | Series B |
| Scottish Investment Bank (Scottish Enterprise) | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Three presentations scheduled at the AACR 2026 Annual meeting.
- Mar 23, 2026
Launched SMARCA2 degraders for NSCLC treatment.
Amphista Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Amphista Therapeutics's valuation, stock price, and market status.